Berlin, 13 December 2018 – The Supervisory Board of Medios AG has appointed Mr. Christoph Prußeit as a member of the Management Board and Chief Innovation Officer (CIO) with effect from 1 January 2019. In this position, he will, among others, be in charge of the Manufacturing division. His appointment means that he will join Manfred Schneider (Chief Executive Officer, CEO), Matthias Gärtner (Chief Financial Officer, CFO) and Mi-Young Miehler (Chief Operating Officer, COO) as the fourth member of the Management Board.
Yann Samson, Chairman of the Supervisory Board of Medios AG: ‘With Christoph Prußeit, we are pleased to appoint a proven expert in the area of pharmaceuticals production and safety to the Management Board of Medios AG. As manager of our subsidiary Medios Individual, he has extensive practical experience in preparing patient-specific antiviral and antibiotic solutions and in the production of parenteral nutrition solutions while strictly observing the highest quality standards. He therefore adds key areas of expertise to the Management Board and can further expedite the company’s growth.’
Mr. Prußeit (30) began his career as a specialized pharmacist with BerlinApotheke Schneider & Oleski oHG in 2014, where he became head of the Sterile Laboratory division. Since 2017, he has been Managing Director of Medios Individual GmbH.
Christoph Prußeit, future member of the Management Board of Medios AG: ‘I would like to thank the Supervisory Board for entrusting me with the responsibility of overseeing the Manufacturing division as member of the Management Board and Chief Innovation Officer. The improvement of pharmaceutical safety is becoming an increasingly important issue in Germany. As a GMP-certified manufacturer, we have a good chance of benefiting from this development.’
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.